Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Liquidia CorporationNASDAQ: LQDA
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue growth accelerates
Q2 FY2026 cost of revenue of $11.55M rose 794.0% year over year, ahead of the +492.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 4.9% from the prior quarter. Over 3 fiscal years it compounded at +66.7% a year.
Context
- Cost of revenue amounted to 8.4% of revenue in FY2025, down 33.6 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +794.0% holds above the trailing-twelve-month pace of +492.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 13.24M USD
- Year-over-year change
- +125.2%
- 4-year CAGR
- +44.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.24M | +125.2% |
| FY2024 | 2024-12-31 | 5.88M | +103.6% |
| FY2023 | 2023-12-31 | 2.89M | +1.0% |
| FY2022 | 2022-12-31 | 2.86M | -5.4% |
| FY2021 | 2021-12-31 | 3.02M | — |
Cost of Revenue vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +492.3% is the highest of 4, against a peer median of +28.9%.
- Cost of revenue amounts to 7.5% of revenue for LQDA, versus a peer median of 13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $437.2M USD | +28.9% | +37.9% | 13.9% | |
| LTM Jun 2026 | $190.3M USD | +96.8% | +31.3% | 16.7% | |
| LTM Jun 2026 | $33.93M USD | +492.3% | +66.7% | 7.5% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 0 SEK | -100.0% | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LQDA) | — | +28.9% | +34.6% | 13.9% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.85M | 15.94M | 17.49M | 14M | 158.32M |
| Cost of Revenue | 3.02M | 2.86M | 2.89M | 5.88M | 13.24M |
| Gross Profit | 9.83M | 13.08M | 14.6M | 8.12M | 145.08M |
| Gross Margin | 76.5% | 82.1% | 83.5% | 58.0% | 91.6% |
| Research & Development | 20.52M | 19.44M | 43.24M | 47.84M | 39.28M |
| Selling, General & Admin | 23.11M | 32.41M | 44.74M | 81.57M | 157.18M |
| Operating Expenses | 43.63M | 51.85M | 87.98M | 129.41M | 196.45M |
| Depreciation & Amortization | 5.61M | 3.65M | 2.18M | 2.2M | 1.53M |
| EBITDA | (28.21M) | (35.03M) | (70.05M) | (115.71M) | (43.22M) |
| EBITDA Margin | -219.4% | -219.8% | -400.6% | -826.7% | -27.3% |
| Operating Income | (33.8M) | (38.77M) | (73.38M) | (121.29M) | (51.38M) |
| Operating Margin | -263.0% | -243.3% | -419.6% | -866.6% | -32.5% |
| Interest Income | 33K | 1.09M | 3.47M | 7.65M | 6.62M |
| Interest Expense | 762K | 2.34M | 6.27M | 12.49M | 24.17M |
| Other Income / Expenses | (782K) | (2.25M) | (5.12M) | (9.1M) | (17.55M) |
| Income Before Tax | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Pre-Tax Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Net Margin | -269.0% | -257.4% | -448.9% | -931.7% | -43.5% |
| EPS (Basic) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| EPS (Diluted) | (0.70) | (0.67) | (1.21) | (1.66) | (0.80) |
| Weighted Avg Shares | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
| Weighted Avg Shares (Diluted) | 49.68M | 60.96M | 64.99M | 78.71M | 86.06M |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.